

Status: Currently Official on 17-Feb-2025
Official Date: Official as of 01-Dec-2016
Document Type: USP Monographs
DocId: GUID-03118A2A-E00B-4789-830D-FAD181D0DFD8_1_en-US
DOI: https://doi.org/10.31003/USPNF_M1803_01_01
DOI Ref: fr2lx

© 2025 USPC
Do not distribute

Tramadol Hydrochloride and Acetaminophen Compounded Oral Suspension

DEFINITION

Tramadol Hydrochloride and Acetaminophen Compounded Oral Suspension contains NLT 90.0% and NMT 110.0% of the labeled amounts of tramadol hydrochloride ($C_{16}H_{25}NO_2 \cdot HCl$) and acetaminophen ($C_8H_9NO_2$).
Prepare Tramadol Hydrochloride and Acetaminophen Compounded Oral Suspension containing 7.5 mg/mL of tramadol hydrochloride and 65 mg/mL of acetaminophen as follows (see [Pharmaceutical Compounding—Nonsterile Preparations \(795\)](#)).

Tramadol Hydrochloride and Acetaminophen tablets ^a	750 mg of tramadol hydrochloride and 6500 mg of acetaminophen
Vehicle: a 1:1 mixture of Ora-Sweet ^b (sugar-free) and Ora-Plus, ^b a sufficient quantity to make	100 mL

- ^a Ultracet 37.5-mg/325-mg tablets, Ortho-McNeil Pharmaceutical, Inc., Raritan, NJ.
^b Paddock Laboratories, Minneapolis, MN.

Calculate the required quantity of each ingredient for the total amount to be prepared. Place the required number of *Tramadol Hydrochloride and Acetaminophen tablets* in a suitable mortar, and comminute to a fine powder. Add the *Vehicle* in small portions, and triturate to make a smooth paste. Add increasing volumes of the *Vehicle* to make a tramadol hydrochloride and acetaminophen liquid that is pourable. Transfer the contents of the mortar, stepwise and quantitatively, to a calibrated bottle. Add enough of the *Vehicle* to bring to final volume, and mix well.

ASSAY

• TRAMADOL HYDROCHLORIDE

Solution A: 20 mM of phosphoric acid and 4 g/L of sodium 1-hexane sulfonate
Mobile phase: Acetonitrile and *Solution A* (50:50). Filter and degas.
Diluent: Acetonitrile and water (50:50)
Standard solution: 0.15 mg/mL of [USP Tramadol Hydrochloride RS](#) in *Diluent*
Sample solution: Shake thoroughly by hand each bottle of Oral Suspension. Prepare 0.15 mg/mL of tramadol hydrochloride from Oral Suspension and *Diluent*, and centrifuge.

Chromatographic system

(See [Chromatography \(621\)](#), [System Suitability](#).)

Mode: LC
Detector: UV 275 nm
Column: 4.6-mm × 25-cm; 5-μm packing L1
Column temperature: 30°
Flow rate: 1.0 mL/min
Injection volume: 5 μL

System suitability

Sample: *Standard solution*
[NOTE—The retention time for tramadol hydrochloride is about 6 min.]
Suitability requirements
Relative standard deviation: NMT 2.0% for replicate injections

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of tramadol hydrochloride ($C_{16}H_{25}NO_2 \cdot HCl$) in the portion of Oral Suspension taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response from the *Sample solution*

r_S = peak response from the *Standard solution*

C_S = concentration of [USP Tramadol Hydrochloride RS](#) in the *Standard solution* (mg/mL)

C_U = nominal concentration of tramadol hydrochloride in the *Sample solution* (mg/mL)

Acceptance criteria: 90.0%–110.0%

• **ACETAMINOPHEN**

Mobile phase: Acetonitrile and water (70:30). Filter and degas.

Standard solution: 65 µg/mL of [USP Acetaminophen RS](#) in *Mobile phase*

Sample solution: Shake thoroughly by hand each bottle of Oral Suspension. Prepare 65 µg/mL of acetaminophen from Oral Suspension and *Mobile phase*, and centrifuge.

Chromatographic system

(See [Chromatography \(621\)](#), [System Suitability](#).)

Mode: LC

Detector: UV 275 nm

Column: 4.6-mm × 25-cm; 5-µm packing L1

Column temperature: 30°

Flow rate: 1.0 mL/min

Injection volume: 5 µL

System suitability

Sample: *Standard solution*

[NOTE—The retention time for acetaminophen is about 2 min.]

Suitability requirements

Relative standard deviation: NMT 2.0% for replicate injections

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of acetaminophen ($C_8H_9NO_2$) in the portion of Oral Suspension taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response from the *Sample solution*

r_S = peak response from the *Standard solution*

C_S = concentration of [USP Acetaminophen RS](#) in the *Standard solution* (µg/mL)

C_U = nominal concentration of acetaminophen in the *Sample solution* (µg/mL)

Acceptance criteria: 90.0%–110.0%

SPECIFIC TESTS

- **pH (791):** 3.8–4.8

ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Package in tight, light-resistant containers. Store in a refrigerator or at controlled room temperature.
- **BEYOND-USE DATE:** NMT 90 days after the date on which it was compounded, when stored in a refrigerator or at controlled room temperature
- **LABELING:** Label to indicate that it is to be well shaken before use, and to state the *Beyond-Use Date*.
- **USP REFERENCE STANDARDS (11).**
[USP Acetaminophen RS](#)
[USP Tramadol Hydrochloride RS](#)

Topic/Question	Contact	Expert Committee
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN COMPOUNDED ORAL SUSPENSION	Brian Serumaga Science Program Manager	CMP2020 Compounding 2020
REFERENCE STANDARD SUPPORT	RS Technical Services RSTECH@usp.org	CMP2020 Compounding 2020

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. PF 41(1)

Current DocID: GUID-03118A2A-E00B-4789-830D-FAD181D0DFD8_1_en-US

DOI: https://doi.org/10.31003/USPNF_M1803_01_01

DOI ref: [fr2lx](#)

OFFICIAL